Inhibition of xanthine oxidase in the acute phase of myocardial infarction prevents skeletal muscle abnormalities and exercise intolerance.
Animals
Cell Hypoxia
Cell Line
Disease Models, Animal
Enzyme Inhibitors
/ pharmacology
Exercise Tolerance
/ drug effects
Febuxostat
/ pharmacology
Male
Mice, Inbred C57BL
Mitochondria, Muscle
/ drug effects
Muscle Fibers, Skeletal
/ drug effects
Muscle Strength
/ drug effects
Muscle, Skeletal
/ drug effects
Muscular Atrophy
/ enzymology
Myocardial Infarction
/ drug therapy
Reactive Oxygen Species
/ metabolism
Ribosomal Protein S6 Kinases, 70-kDa
/ metabolism
TOR Serine-Threonine Kinases
/ metabolism
Time Factors
Xanthine Oxidase
/ antagonists & inhibitors
Heart failure
Mitochondria
Reactive oxygen species
Skeletal muscle atrophy
Uric acid
Journal
Cardiovascular research
ISSN: 1755-3245
Titre abrégé: Cardiovasc Res
Pays: England
ID NLM: 0077427
Informations de publication
Date de publication:
22 02 2021
22 02 2021
Historique:
received:
15
01
2020
revised:
01
04
2020
pubmed:
14
5
2020
medline:
5
1
2022
entrez:
14
5
2020
Statut:
ppublish
Résumé
Exercise intolerance in patients with heart failure (HF) is partly attributed to skeletal muscle abnormalities. We have shown that reactive oxygen species (ROS) play a crucial role in skeletal muscle abnormalities, but the pathogenic mechanism remains unclear. Xanthine oxidase (XO) is reported to be an important mediator of ROS overproduction in ischaemic tissue. Here, we tested the hypothesis that skeletal muscle abnormalities in HF are initially caused by XO-derived ROS and are prevented by the inhibition of their production. Myocardial infarction (MI) was induced in male C57BL/6J mice, which eventually led to HF, and a sham operation was performed in control mice. The time course of XO-derived ROS production in mouse skeletal muscle post-MI was first analysed. XO-derived ROS production was significantly increased in MI mice from Days 1 to 3 post-surgery (acute phase), whereas it did not differ between the MI and sham groups from 7 to 28 days (chronic phase). Second, mice were divided into three groups: sham + vehicle (Sham + Veh), MI + vehicle (MI + Veh), and MI + febuxostat (an XO inhibitor, 5 mg/kg body weight/day; MI + Feb). Febuxostat or vehicle was administered at 1 and 24 h before surgery, and once-daily on Days 1-7 post-surgery. On Day 28 post-surgery, exercise capacity and mitochondrial respiration in skeletal muscle fibres were significantly decreased in MI + Veh compared with Sham + Veh mice. An increase in damaged mitochondria in MI + Veh compared with Sham + Veh mice was also observed. The wet weight and cross-sectional area of slow muscle fibres (higher XO-derived ROS) was reduced via the down-regulation of protein synthesis-associated mTOR-p70S6K signalling in MI + Veh compared with Sham + Veh mice. These impairments were ameliorated in MI + Feb mice, in association with a reduction of XO-derived ROS production, without affecting cardiac function. XO inhibition during the acute phase post-MI can prevent skeletal muscle abnormalities and exercise intolerance in mice with HF.
Identifiants
pubmed: 32402072
pii: 5836830
doi: 10.1093/cvr/cvaa127
doi:
Substances chimiques
Enzyme Inhibitors
0
Reactive Oxygen Species
0
Febuxostat
101V0R1N2E
Xanthine Oxidase
EC 1.17.3.2
mTOR protein, mouse
EC 2.7.1.1
Ribosomal Protein S6 Kinases, 70-kDa
EC 2.7.11.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
805-819Informations de copyright
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.